CXL could treat stages of keratoconus

Aug 15, 2013

Corneal collagen crosslinking (CXL) could successfully treat certain stages of keratoconus, according to a recent published paper.

Corneal collagen crosslinking (CXL) could successfully treat certain stages of keratoconus, according to a recent published paper.

Dr Ziad Hassan et al., Orbident Refractive Surgery and Medical Centre, Medical and Health Science Center, Debrecen, Hungary, treated a total of 38 eyes of 25 patients with the CXL technique. The team performed slit-lamp examination tests, visual acuity tests and pachymetry measurements on all eyes. Corneal topography was used to obtain numerical data. The group also used simulated keratometry (K1, K2), cylinder value (CYL), surface asymmetry index (SAI), irregular astigmatism index (IAI), surface regulatory index (SRI), average corneal power (ACP), and corneal eccentricity index (CEI).

There were no significant changes in the values of mean K1, cylinder, SAI, IAI, SRI, K2 and CEI at the end of the examination period. Uncorrected visual acuity did not change, but best-corrected visual acuity changed from 0.21 ± 0.17 to 0.12 ± 0.11 in logMAR scale. However, this was not significant.

There were no changes in intraocular pressure, the cornea remained clear during the follow-up period and there were no occurrences of corneal thinning. CXL can offer a way to prevent progression in keratometric indices.

To read the abstract please visit the European Journal of Ophthalmology.

x